Ensysce Biosciences (ENSC) vs Senti Biosciences (SNTI)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Senti Biosciences is the larger company by market cap ($10.0 million vs $8.9 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ENSC | SNTI |
|---|---|---|
| Share price | $0.458 | $0.3217 |
| Market cap | $8.91M | $10.02M |
| 1-day change | +6.66% | -2.52% |
| YTD return | — | -69.07% |
| 1-year return | — | -81.93% |
| 5-year return | — | -99.68% |
| EPS (TTM) | $-2.47 | $-1.72 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $2.75 | $2.88 |
| 52-week low | $0.23 | $0.29 |
| Distance from 52-week high | -83.35% | -88.83% |
| Analyst consensus | none | none |
| Avg. price target upside | +1701.31% | +4096.46% |
| Average volume | 14.21M | 573.78K |
| Shares outstanding | 19.46M | 31.15M |
| Employees | 8 | 39 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Ensysce Biosciences
ENSC stock →Ensysce Biosciences, Inc., a clinical-stage pharmaceutical company, develops prescription drugs for severe pain relief in opioid misuse, abuse, and overdose in the United States. It develops products using Trypsin Activated Abuse Protection (TAAP) platform, designed to release clinically effective drugs only when exposed to specific physiological conditions; and Multi-Pill Abuse Resistance (MPAR) platform, an over-dose protection opioid prodrug technology.
Healthcare · Biotechnology · 8 employees
About Senti Biosciences
SNTI stock →Senti Biosciences Holdings, Inc., a clinical stage biotechnology company, develops cell and gene therapies engineered with its gene circuit platform technologies for patients living with incurable diseases. The company's lead product candidates utilize off-the-shelf healthy adult donor derived natural killer (NK) cells to create CAR-NK cells outfitted with gene circuit technologies in various oncology indications with unmet need.
Healthcare · Biotechnology · 39 employees
ENSC vs SNTI FAQ
Which is bigger, Ensysce Biosciences or Senti Biosciences?
Senti Biosciences (SNTI) is larger, with a market capitalization of $10.02M compared with $8.91M for Ensysce Biosciences (ENSC).
Are Ensysce Biosciences and Senti Biosciences in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.